<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269850</url>
  </required_header>
  <id_info>
    <org_study_id>tfm-gvhd-2019</org_study_id>
    <nct_id>NCT04269850</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD</brief_title>
  <acronym>JAK-FMT</acronym>
  <official_title>Pilot Study of Fecal Microbiota Transplantation in Combination With Ruxolitinib and Steroids for Severe Acute Intestinal Graft-versus-host-disease After Allogeneic Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Therapy of severe intestinal graft-versus-host disease (GVHD) despite the introduction of
      novel target agents is associated with worse outcome compared to the other forms. Response to
      steroids is observed only in about 10% of patients. The most promising approaches are JAK
      inhibition and fecal microbiota transplantation. In this pilot study we evaluate this
      combination treatment in the first line.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute intestinal GVHD grade III-IV after allogeneic stem cell transplantation the form with
      low effectiveness of corticosteroids. Despite high response rate to systemic immunosupressive
      agents, long term survival in this group is poor due to recurrent septic episodes and gut
      colonization with multidrug resistant bacteria. Fecal microbiota transplantation (FMT) from a
      healthy allogeneic donor, allows to restore numerous local and systemic microbiota functions,
      including immunomodulation and thus to reduce/stop the manifestations of GVHD. The
      therapeutic mechanism of action of FMT is based on competition for nutrients between obligate
      and pathologic bacterial strains, direct growth inhibition of the pathological pathogens,
      host immune system modulation, especially T-reg homeostasis, through interaction with the
      normal microbiota.In this pilot trial we combine FMT with ruxolitinib and steroids, one of
      the most effective option for refractory GVHD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>365 days</time_frame>
    <description>Time from treatment initiation to death or end of follow up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overal response rate</measure>
    <time_frame>100 days</time_frame>
    <description>Evaluated with 2009 consensus criteria and 2016 severity grading on days +7,+28, +56, +100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events based on CTC AE 5.0</measure>
    <time_frame>100 days</time_frame>
    <description>Based on CTC AE 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious complications</measure>
    <time_frame>100 days</time_frame>
    <description>Cumulative incidence of bacterial, viral and fungal infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to steroid discontinuation</measure>
    <time_frame>100 days</time_frame>
    <description>Time from treatment initiation to steroid cessation without GVHD flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to ruxolitinib discontinuation</measure>
    <time_frame>365 days</time_frame>
    <description>Time from treatment initiation to ruxolitinib cessation without GVHD flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to systemic immunosuppression discontinuation</measure>
    <time_frame>365 days</time_frame>
    <description>Time from treatment initiation to cessation of all systemic immunosupression without GVHD flare</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Intestinal GVHD</condition>
  <arm_group>
    <arm_group_label>FMT+ruxolitinib+steroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ruxolitinib 10 mg bid, fecal microbiota transplantation 2 caps/kg single dose, methylprednisone 0.5 mg/kg bid</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>allogeneic fecal microbiota</intervention_name>
    <description>Single dose of capsules with fecal transplant (capsules for adults - 400-815mg, for adolescents - 280-500mg, for children - 160-320mg) - 2 capsules/kg body weight, divided in two consecutive days Additional supportive therapy after FMT include omeprazole 40mg po, inulin 1gr x 4 times a day po, metoclopramide 40mg po.</description>
    <arm_group_label>FMT+ruxolitinib+steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib</intervention_name>
    <description>Ruxolitinib starting dose 10 mg bid. In case of grade 4 hematological toxicity dose can be reduced by 25-75%.</description>
    <arm_group_label>FMT+ruxolitinib+steroids</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisone</intervention_name>
    <description>Methylprednisone starting dose 0.5 mg/kg bid IV or oral, with subsequent tapper by 0.1 mg/kg every 5 days.</description>
    <arm_group_label>FMT+ruxolitinib+steroids</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 5-70 years

          -  Histologically confirmed gastrointestinal acute GVHD

          -  Grade III-IV gastrointestinal GVHD based on 2016 MAGIC criteria

          -  Ability for oral drug intake

          -  Signed informed consent

        Exclusion Criteria:

          -  Requirement for oxigen and/or vasopressor support

          -  Respiratory distress &gt;grade I

          -  Severe organ dysfunction: AST or ALT &gt;5 upper normal limits, bilirubin &gt;1.5 upper
             normal limits, creatinine &gt;2 upper normal limits,creatinine clearance &lt; 60 mL/min

          -  Ongoing fluconazole therapy

          -  Any malignancy requiring systemic therapy at the time of enrollment

          -  Mixed chimerism at last evaluation

          -  Uncontrolled bacterial or fungal infection at the time of enrollment

          -  Requirement for vasopressor support at the time of enrollment

          -  Karnofsky index &lt;30%

          -  Severe concurrent illness that can interfere with study procedures

          -  Somatic or psychiatric disorder making the patient unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris Afanasyev, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pavlov First Saint-Petersburg State Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oleg Goloshchapov</last_name>
    <phone>+79219792913</phone>
    <email>golocht@yandex.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maksim Kucher, MD, PhD</last_name>
    <phone>+79219939902</phone>
    <email>doctorkucher@yandex.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pavlov First Saint-Petersburg State Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleg Goloshchapov</last_name>
      <phone>+79219792913</phone>
      <email>golocht@yandex.ru</email>
    </contact>
    <contact_backup>
      <last_name>Maksim Kucher, PhD, MD</last_name>
      <phone>+79219939902</phone>
      <email>doctorkucher@yandex.ru</email>
    </contact_backup>
    <investigator>
      <last_name>Alexey Chukhlovin, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan Moiseev, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maksim Kucher, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Oleg Goloshchapov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Petersburg State Pavlov Medical University</investigator_affiliation>
    <investigator_full_name>Ivan S Moiseev</investigator_full_name>
    <investigator_title>Deputy Director for research, Raisa Gorbacheva Memorial Research Institute for Pediatric Oncology, Hematology and Transplantation Affiliation: St. Petersburg State Pavlov Medical University</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

